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Abstract
Aims: We aimed to investigate the rapid induction of therapeutic hypothermia using the ZOLL Proteus 
Intravascular Temperature Management System in patients with anterior ST-elevation myocardial infarction 
(STEMI) without cardiac arrest.
Methods and results: A total of 50 patients were randomised; 22 patients (88%; 95% confidence interval 
[CI]: 69-97%) in the hypothermia group and 23 patients (92%; 95% CI: 74-99) in the control group com-
pleted cardiac magnetic resonance imaging at four to six days and 30-day follow-up. Intravascular tempera-
ture at coronary guidewire crossing after 20.5 minutes of endovascular cooling decreased to 33.6°C (range 
31.9-35.5°C). There was a 17-minute (95% CI: 4.6-29.8 min) cooling-related delay to reperfusion. In “per 
protocol” analysis, median infarct size/left ventricular mass was 16.7% in the hypothermia group versus 
23.8% in the control group (absolute reduction 7.1%, relative reduction 30%; p=0.31) and median left ven-
tricular ejection fraction (LVEF) was 42% in the hypothermia group and 40% in the control group (absolute 
reduction 2.4%, relative reduction 6%; p=0.36). Except for self-terminating paroxysmal atrial fibrillation 
(32% versus 8%; p=0.074), there was no excess of adverse events in the hypothermia group.
Conclusions: We rapidly and safely cooled patients with anterior STEMI to 33.6°C at the time of coro-
nary guidewire crossing. This is ≥1.1°C lower than in previous cooling studies. Except for self-terminating 
atrial fibrillation, there was no excess of adverse events and no clinically important cooling-related delay 
to reperfusion. A statistically non-significant numerical 7.1% absolute and 30% relative reduction in infarct 
size warrants a pivotal trial powered for efficacy. ClinicalTrials.gov Identifier: NCT02509832
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Abbreviations
BSAS bedside shivering assessment scale
CI confidence interval
cMR cardiac magnetic resonance imaging
EF ejection fraction
IS infarct size
LV left ventricle
PCI percutaneous coronary intervention
STEMI ST-elevation myocardial infarction
Introduction
Experimental studies in different animal species have shown that 
mild hypothermia, induced before reperfusion of acute coronary 
occlusion, reduces infarct size (IS)1-6. Cooling prior to reperfusion 
therefore appeared a promising adjunct to primary percutaneous 
coronary intervention (PCI) in ST-elevation myocardial infarc-
tion (STEMI) to reduce IS further and thereby improve clini-
cal outcome7,8. Despite promising experimental evidence, except 
for RAPID MI-ICE9, randomised clinical trials including COOL 
MI10, ICE-IT11, CHILL-MI12 and VELOCITY13 have failed to 
show a significant reduction in IS, although endovascular cool-
ing appeared to be safe and well tolerated. Despite neutral over-
all results, subsequent unpublished post hoc subgroup analysis of 
COOL MI and ICE-IT, and combined analysis of RAPID MI-ICE 
and CHILL-MI14 showed significant reduction in IS in a subgroup 
of early presenters with anterior STEMI who were cooled below 
35°C prior to reperfusion. Accordingly, benefits of therapeutic 
hypothermia may be achieved in properly selected patients by 
using a rapid cooling to decrease core temperature sufficiently 
prior to the opening of the infarct-related artery.
In the present pilot study, we therefore selected patients with 
anterior STEMI within six hours of symptom onset and tested the 
new ZOLL® Proteus™ Intravascular Temperature Management 
System™ (ZOLL Medical Corporation, Chelmsford, MA, USA) 
(Figure 1), which is, according to technical specifications, signi-
ficantly more powerful (cooling rate 9.6°C/hour, 430 watts) than 
the Reprieve™ System (cooling rate 3.3°C/hour, 180 watts) 
(Radiant Medical, Redwood City, CA, USA) used in COOL MI10 
and the InnerCool™ Accutrol™ System (cooling rate 3.6°C/hour, 
175 watts) (ZOLL Medical Corporation) used in the ICE-IT11, 
RAPID MI-ICE9 and CHILL-MI12 trials. The primary goals of our 
pilot study were to investigate the feasibility and safety of more 
rapid and profound cooling than in previous trials and to gather 
information for sample size calculations for a large pivotal trial. 
Accordingly, this trial was not powered to demonstrate possible 
reductions in IS by hypothermia.
Methods
This was a multicentre, prospective, interventional, randomised con-
trolled, two-arm pilot trial performed at 16 sites in eight countries 
including Zemun, Belgrade, Novi Sad (Serbia), Vienna (Austria), 
Ljubljana (Slovenia), Budapest, Balatonfured, Pecs, Debrecen and 
Miskolc (Hungary), Zabrze, Lodz and Warsaw (Poland), Tallinn 
(Estonia), Basildon (UK) and Lund (Sweden). Each centre had to 
Figure 1. ZOLL Proteus Intravascular Temperature Management System.
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COOL AMI EU pilot trial
perform up to four successful roll-in patients before starting to ran-
domise. All procedures were carried out in accordance with the 
Declaration of Helsinki and the local/national ethics committees 
approved the study protocol. All patients gave written informed 
consent prior to inclusion in the study. An independent Data and 
Safety Monitoring Board, consisting of physicians independent of 
the trial sponsor and operational leadership, monitored the safety of 
the study based on access to unblinded data.
PATIENTS
The study enrolled patients ≥18 years of age with a duration of 
symptoms of ≤6 hrs presenting with an anterior STEMI with per-
sistent ST-segment elevation of >0.2 mV in two contiguous leads 
at arrival to the catheterisation laboratory and before randomisa-
tion. Patients with resuscitated cardiac arrest, previous acute myo-
cardial infarction, PCI or coronary artery bypass grafting, Killip 
class II-IV at presentation, atrial fibrillation, end-stage kidney 
disease or hepatic failure, recent stroke, coagulopathy and preg-
nancy were excluded. Eligible patients were randomised 1:1 
using a computer generating system to the hypothermia arm (pri-
mary PCI+cooling+standard care) or to the control arm (primary 
PCI+standard care alone).
All patients received acetylsalicylic acid, heparin and P2Y12 
receptor blockade. Glycoprotein IIb/IIIa inhibitors were adminis-
tered at the discretion of the treating physician.
HYPOTHERMIA PROTOCOL
Patients assigned to the hypothermia group were initially admin-
istered 60 mg of oral buspirone and pethidine (meperidine) as 
an intravenous loading dose of 1 mg/kg (maximum 100 mg) or 
0.5 mg/kg if the patient had already received morphine. After 
15 minutes, an additional dose of 0.5 mg/kg was given and con-
tinued as an infusion at 25 mg/hour (up to 80 kg patient) or 35 mg/
hour (>80 kg patient) for the duration of the device deployment. 
Patients were placed on a Bair Hugger™ (3M, Maplewood, MN, 
USA) which covered the catheterisation table for skin counter 
warming. Continuous verbal contact with the patient was main-
tained. Respiratory rate and pulse oximetry were monitored with 
targets of >10 breaths/minute and arterial oxygen saturation of 
≥90%. Cooling was initiated with a forced infusion of up to 1 L of 
cold saline (4°C) using pressure bags and continued by the ZOLL 
Proteus Intravascular Temperature Management System. The cool-
ing catheter was inserted via the femoral vein into the inferior 
vena cava with the tip positioned at the level of the diaphragm. 
The Proteus temperature probe (X-Probe; ZOLL) was put through 
the catheter lumen to the right atrium for continuous measurement 
of core temperature. The console temperature was set to 32.0°C 
and cooling at maximum power started. Following placement 
and activation of the cooling catheter, arterial puncture was per-
formed and coronary angiography/PCI conducted in a standard 
fashion. An interval of 18 minutes of endovascular cooling from 
catheter activation to coronary guidewire passing across the acute 
occlusion was advised. Cooling was maintained for three hours, 
followed by active rewarming at the rate of 1.0°C/hour to attain 
36.0°C. The catheter was then removed. Shivering was continu-
ously assessed by the bedside shivering assessment scale (BSAS) 
using the following categories:
0 - No shivering on palpation of the masseter, neck or chest wall.
1 - Shivering localised to the neck and/or thorax only.
2 - Shivering with gross movement of the neck, thorax and upper 
extremities.
3 - Shivering involving gross movements of the trunk, upper and 
lower extremities.
If BSAS was ≥2, additional boluses of pethidine (25 mg) were 
used and infusion increased to a maximum of 35 mg/hour. If shiv-
ering persisted, the Proteus target temperature was raised stepwise 
by 0.5°C until shivering disappeared.
CARDIAC MAGNETIC RESONANCE IMAGING
After four to six days, patients underwent cardiac magnetic reso-
nance imaging (cMR) in the supine position. After initial scout 
images to locate the heart and the standard imaging planes, 
0.2 mmol/kg of body weight of an extracellular gadolinium-based 
contrast agent was administered. For evaluation of left ventricular 
(LV) function, early contrast-enhanced steady-state free precession 
(CE-SSFP) cine images were obtained approximately five minutes 
after contrast injection (slice thickness 8 mm with no slice gap, 
temporal resolution 20 to 30 frames per cardiac cycle, in-plane 
resolution 1.5 mm×1.5 mm). For infarct visualisation, late gado-
linium enhancement (LGE) images were acquired 15-20 minutes 
after administration of the contrast agent using an inversion-recov-
ery gradient-echo sequence (slice thickness 8 mm with no slice 
gap, in-plane resolution 1.5 mm×1.5 mm). Inversion time was 
manually adjusted to null the signal from viable myocardium, typ-
ically 200-300 milliseconds. Cine and LGE images were acquired 
in the short-axis view, from base to apex, and in the three standard 
long-axis views (two-chamber, four-chamber and left ventricular 
outflow tract views). Analyses of cMR images were performed by 
an independent core lab (Imacor AB, Lund, Sweden) using post-
processing software (Segment EWA)15. IS divided by LV mass (IS/
LV mass) and LV ejection fraction (EF) were measured.
STUDY ENDPOINTS
The primary endpoint was the proportion of all subjects who com-
pleted the follow-up and cMR imaging requirements at 30 days 
following trial enrolment and randomisation.
Secondary efficacy endpoints were IS/LV mass and LVEF 
at day 4-6. Secondary safety endpoints were followed within 
30 days (±7 days) after the index procedure and included death, 
target vessel revascularisation, stent thrombosis, arrhythmias, 
cardiogenic shock, pulmonary oedema, deep venous thrombosis/
pulmonary embolism, vascular complications requiring interven-
tion, cooling catheter access site and systemic infection. Clinical 
events were collected by adverse event and serious adverse 
event reporting based on hospital charts reviewed by independ-
ent monitors.
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STATISTICAL ANALYSIS
In this pilot study, evaluation of retention was calculated with 
number and proportion with exact 95% confidence interval. For 
all clinical, angiographic, periprocedural characteristics and safety 
outcomes, mean, standard deviation, median, range or frequency 
and proportion were reported. For categorical variables, Fisher’s 
exact test or the chi-square test was used to compare between the 
two treatment groups. For continuous variables including IS/LV 
mass and LVEF, the Wilcoxon rank-sum test and t-test were used 
to compare between the two treatment groups as appropriate. No 
imputation was carried out for missing data. All tests were two-
sided. A p-value <0.05 was considered statistically significant. All 
statistical analyses were performed using SAS 9.4 (SAS Institute, 
Cary, NC, USA).
Results
From May 2016 to February 2017, among 273 screened patients 
with anterior STEMI, 50 patients were enrolled and randomised 
to either the cooling group (n=25) or the control group (n=25) 
(Figure 2). Because of acute respiratory failure and cooling sys-
tem malfunction, respectively, two patients randomised to hypo-
thermia did not undergo the cooling procedure. Cooling was 
completed according to protocol in 23 patients and 22 survived 
to day 30. cMR was performed in 22 patients at day 4-6. In the 
control group, 23 patients survived to day 30 with cMR per-
formed in 22 patients at day 4-6. Accordingly, 22 patients (88%; 
95% confidence interval [CI]: 69-97) in the cooling group and 
23 patients (92%; 95% CI: 74-99) in the control group completed 
cMR at 4-6 days and follow-up at 30 days following enrol-
ment and randomisation. Reasons for not performing cMR were 
patient discharge (n=1) in the cooling group and death (n=2) in 
the control group.
Table 1. Clinical, angiographic and periprocedural 
characteristics.
Control
(n=25)
Hypothermia
(n=25)
p-value
Mean age, years 61±13 56±12 0.19
Male gender 20 (80%) 23 (92%) 0.42
Diabetes 4 (16%) 3 (12%) 1.00
Hypertension 19 (76%) 13 (52%) 0.08
Dyslipidaemia 8 (32%) 10 (40%) 0.56
Current smoker 14 (56%) 14 (56%) 1.00
Mean body mass index, kg/m2 26.5±3.6 27.9±3.8 0.19
Symptoms to randomisation, min 174±82 213±73 0.08
Randomisation to first device, 
min 42±23 59±19 0.01
Symptoms to first device, min 209±69 267±73 0.01
Initial IRA TIMI 0/1 21 (88%) 23 (92%) 0.67
Multivessel coronary disease 3 (12%) 1 (4%) 0.61
Thrombus aspiration 8 (32%) 12 (48%) 0.25
Stenting of IRA 25 (100%) 23 (92%) 0.49
Final IRA TIMI 3 23 (92%) 21 (88%) 0.67
Acetylsalicylic acid 25 (100%) 25 (100%) 1.00
Heparin 25 (100%) 25 (100%) 1.00
Prasugrel/ticagrelor 21 (84%) 19 (76%) 0.72
GP llb/llla 12 (48%) 11 (44%) 0.78
Data are presented as “intention to treat”. GP llb/llla: glycoprotein llb/llla 
inhibitor; IRA: infarct-related artery
Randomised (n=50)
Control (n=25)
1 Death (CS, day 1)
Not cooled (n=25)
Survived to day 4-6 (n=24)
– cMRI performed (n=23)
– cMRI analysed (n=22)
1 Death (VSD, day 7)
Survived to day 30 (n=23)
Hypothermia (n=25)
No cooling
– 1 Device malfunction
– 1 ARF
Survived to day 4-6 (n=23)
– cMRI performed (n=22)
– cMRI analysed (n=19)
1 Death (MOF, day 28)
Survived to day 30 (n=22)
Cooled (n=23)
Figure 2. Study flow chart. ARF: acute respiratory failure; 
cMRI: cardiac magnetic resonance imaging; CS: cardiogenic shock; 
MOF: multiple organ failure; VSD: ventricular septal defect
The hypothermia group and the control group were compar-
able in terms of age, gender, body mass index and risk factors 
for coronary disease (Table 1). Mean time delay from symptom 
onset to the first PCI device (balloon or thrombus aspiration cath-
eter) was 267 minutes in the hypothermia group and 209 min-
utes in the control group (p=0.01). Increased total ischaemic time 
in the hypothermia group was predominantly caused by longer 
time from symptom onset to randomisation (213 minutes versus 
174 minutes; p=0.08) and not by the delay from randomisation to 
the first PCI device (59 minutes versus 42 minutes; p=0.01). The 
cooling-related time delay to reperfusion was 17 minutes (95% CI: 
4.6-29.8 minutes). There were no significant differences in angio-
graphic features, primary PCI result or periprocedural medication 
between the groups.
Anti-shivering medication administered before and during the 
cooling included morphine, buspirone and pethidine (Table 2). 
The mean time interval between Proteus system activation and 
coronary guidewire crossing was 20.5 minutes. At this point, mean 
intravascular temperature reached 33.6°C (range 31.9-35.5°C). 
Uncontrolled shivering was documented in two patients (9%). 
The three-hour cooling phase was followed by gradual rewarm-
ing which increased the temperature back to normothermia docu-
mented in the control group during the whole study interval 
(Figure 3).
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Figure 3. Temperature in hypothermia and control groups at baseline 
randomisation, initiation of endovascular cooling, and at guidewire 
crossing, after PCI and during rewarming. Intravascular 
temperature measured by the Proteus catheter in the right atrium for 
the hypothermia group, and tympanic temperature for the control 
group are shown. Representative cooling curve is shown in the right 
lower corner. *p<0.05 versus control.
Table 2. Cooling procedure.
Patients 
randomised to 
hypothermia
(n=25)
Patients undergoing cooling 23 (92%)
Anti-shivering management
Pre-cooling morphine 12 (52%)
Buspirone 60 mg 23 (100%)
Pethidine 23 (100%)
Cumulative pethidine dose, mg* 151±58 (82-325)
Heating blanket 23 (100%)
BSAS shivering score (0-3)** 0 (0-1)
Uncontrolled shivering 2 (9%)
Tympanic temperature at randomisation, °C 36.3±0.07
Intravascular temperature at Proteus insertion, °C 36.0±0.59
Duration of Proteus cooling until guidewire 
crossing, min 20.52±3.93
Intravascular temperature at guidewire  
crossing, °C*
33.6±1.0 
(31.9-35.5)
Total volume of cold saline, ml 1,002±59
Duration of Proteus cooling phase, min 180±82
Duration of Proteus rewarming phase, min 213±96
Time from Proteus implantation to removal, min 418±85
*Mean±SD (minimal to maximal). **Median and interquartile range 
from BSAS score taken every 30 minutes during cooling. BSAS: bedside 
shivering assessment scale
cMR at day 4-6 was analysed in 19 of 22 patients in the hypo-
thermia group and 22 of 23 patients in the control group. Reasons 
for no cMR analysis in the hypothermia group were technically 
inadequate image (n=2) and stent thrombosis with reinfarction 
before cMR (n=1) which would have made interpretation of the 
index IS impossible. In the control group, one image was not read-
able. The numerical difference in IS/LV mass (Figure 4) and LVEF 
(Figure 5) in favour of the hypothermia group at day 4-6 was not 
statistically significant. In “per protocol” analysis, median IS/LV 
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Figure 4. IS/LV mass (%) measured by cardiac magnetic resonance imaging in control and hypothermia patients at day 4-6. A) Intent-to-treat 
population. B) Per-protocol population.
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mass was 16.7% in the hypothermia group versus 23.8% in the 
control group (absolute reduction 7.1%, relative reduction 30%; 
p=0.31) and median LVEF was 42% in the hypothermia group and 
40% in the control group (absolute reduction 2.4%, relative reduc-
tion 6%; p=0.36).
There were no significant differences in adverse events except 
for a strong trend towards more self-terminating paroxysmal atrial 
fibrillation, documented in 32% of cooled patients and 8% in the 
control group (p=0.074) (Table 3). The atrial fibrillation resolved 
spontaneously to sinus rhythm in all patients during the rewarming 
phase. In the hypothermia group, two patients (8%; 95% CI: 1.1-
28.0) had stent thrombosis. Acute stent thrombosis in one patient 
was probably related to stent malpositioning. Subacute stent 
thrombosis on day 5 in another patient might have been associated 
with clopidogrel resistance documented by platelet testing. There 
were no vascular complications, significant bleeding or infection 
related to the access site.
Discussion
In the present pilot study in patients with anterior STEMI, we were 
able to cool conscious patients to 33.6°C prior to coronary guide-
wire crossing using the ZOLL Proteus Intravascular Temperature 
Management System and up to 1 L of concomitant infusion of 
cold saline. Such a reduction in core temperature, achieved within 
approximately 20 minutes from endovascular catheter activation 
and with 17 minutes of cooling-related delay to reperfusion, is at 
least 1.1°C lower than documented in recent cooling trials includ-
ing RAPID-MI ICE9, CHILL-MI12 and VELOCITY13.
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Figure 5. Left ventricular ejection fraction measured by cardiac magnetic resonance imaging in control and hypothermia patients at day 4-6. 
A) Intent-to-treat population. B) Per-protocol population.
Table 3. Adverse events at 30 days.
Control
(n=25)
Hypothermia
(n=25)
p-value
Death 2 (8%) 1 (4%) 1.00
Target vessel revascularisation 0 (0%) 2 (8%) 0.49
Definite/probable stent 
thrombosis 0 (0%) 2 (8%) 0.49
Ventricular fibrillation 2 (8%) 2 (8%) 1.00
Sustained ventricular 
tachycardia 0 (0%) 1 (4%) 1.00
Paroxysmal atrial fibrillation 2 (8%) 8 (32%) 0.07
Bradycardia (<60 min) 1 (4%) 0 (0%) 1.00
Cardiogenic shock 1 (4%) 1 (4%) 1.00
Pulmonary oedema 0 (0%) 1 (4%) 1.00
Arterial hypotension 3 (12%) 3 (12%) 1.00
Pneumonia 1 (4%) 4 (16%) 0.35
Urinary tract infection 2 (8%) 3 (12%) 1.00
Deep venous thrombosis 0 (0%) 1 (4%) 1.00
Uncontrolled shivering 0 (0%) 2 (8%) 0.49
Data are presented as “intention to treat”.
Our cooling protocol with anti-shivering medication and skin 
counter warming appeared to be safe although the number of 
patients in the study is too small to draw a definite conclusion. 
The incidence of ventricular fibrillation and sustained ventricu-
lar tachycardia was comparable in both groups, while paroxysmal 
atrial fibrillation tended to be more frequent in the cooling group. 
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Although an excess of atrial fibrillation has not been reported in 
any of the previous cooling studies, it might have been related 
to more rapid and profound cooling. However, atrial fibrillation 
appeared to be a short-lasting and self-terminating phenomenon 
requiring no additional treatment. We further documented two 
patients with stent thrombosis in the cooling group which might 
have been related to a suboptimal angiographic result or clopi-
dogrel resistance, or might have been a random effect due to the 
small number of patients in our study. Of note, an excess of stent 
thrombosis has never been reported in any of the previous endo-
vascular cooling studies9-12. However, core temperature in our 
study was ≥1.1°C lower and this might have increased platelet 
aggregation16,17. Furthermore, resorption and metabolism of clopi-
dogrel, used in 24% of our hypothermia group, is slower in cooled 
and sedated patients18. Our observation may therefore point to 
possible prothrombotic conditions if intravascular temperature is 
so quickly and strikingly reduced. It also underscores the impor-
tance of selection of the least thrombogenic contemporary drug-
eluting stents, optimal deployment and utilisation of novel P2Y12 
inhibitors rather than clopidogrel in the planned pivotal study. 
Although shivering did not appear to be a significant issue, we 
observed two patients (9%) with uncontrolled shivering, indicat-
ing room for further improvement in anti-shivering medication to 
increase the comfort of patients.
Although not statistically significant, a numerical reduction in 
median IS/LV mass (7.1% absolute and 30% relative) was docu-
mented in the hypothermia group compared to controls in the per 
protocol population, warranting further evaluation for efficacy in 
a fully powered pivotal trial. Of note, a 5.1% absolute reduction 
in IS in the “Stent Versus Thrombolysis for Occluded Coronary 
Arteries in Patients With Acute Myocardial Infarction” trial is gen-
erally accepted as a clinically meaningful result for cardioprotec-
tion trials19. Moreover, IS of >29.8% was shown to be significantly 
correlated with increased mortality or heart failure hospitalisation 
within one year20. In our study, 16% of the patients in the hypo-
thermia group had an IS >29.8% compared to 41% of patients in 
the control group (p=0.16).
Limitations
Our results on IS reduction, however, should be interpreted in the 
light of several limitations. Firstly, the study was obviously not 
powered to detect significant difference in IS/LV mass and LVEF. 
Based on the results of this pilot study, assuming a standard devia-
tion of 12%, a two-tailed t-test of difference between the means, 
and a normal distribution, the sample size required is 372 patients 
(186 in each arm) for 80% power and 5% level of significance to 
detect a 20% relative (3.5% absolute) reduction in IS/LV mass. 
With a further assumption of up to 20% loss in cMR and follow-
up, the pivotal trial would need to enrol 468 patients (234 in each 
arm). Secondly, the total ischaemic time was 60 minutes longer 
in cooled patients, mainly driven by longer time to randomisa-
tion because the cooling-related delay was only 17 minutes. This 
unfortunate imbalance, representing a significant bias against 
hypothermia, may happen in small trials such as ours despite ran-
domisation. Thirdly, total ischaemic time in our cooled patients 
(260 minutes) was also significantly longer than in CHILL-MI 
(132 minutes)12, VELOCITY (172 minutes)13, RAPID MI ICE 
(174 minutes)9 and COOL MI (205 minutes)10, which again 
may represent a bias against hypothermia. Pooled analysis of 
CHILL-MI and RAPID MI ICE demonstrated that hypothermia 
before reperfusion has significantly better effectiveness in early 
presenters14. Last but not least, our study is lacking core laboratory 
measurements of cardiac troponin, which would represent a cMR-
independent estimate of IS. These are all important lessons learned 
for the planned pivotal study.
Conclusions
Using the ZOLL Proteus Intravascular Temperature Management 
System and up to 1 L of cold saline, we were able to cool con-
scious patients with anterior STEMI to 33.6°C at the time of coro-
nary guidewire crossing, which was ≥1.1°C lower than in previous 
cooling studies. Such rapid cooling resulted in 17 minutes of cool-
ing-related delay to reperfusion. Our cooling protocol, including 
anti-shivering medication and skin counter warming, appeared to 
be safe and well tolerated. Although this pilot trial was underpow-
ered, the improved delivery of hypothermia resulted in a numer-
ical reduction of IS, which supports a further pivotal study to 
evaluate efficacy in a larger population.
Impact on daily practice
This pilot trial, which demonstrated that we can cool conscious 
patients with anterior STEMI to 33.6°C at the time of coro-
nary guidewire crossing which is ≥1.1°C lower than in previ-
ous cooling trials, opens the door for an adequately powered 
pivotal trial with the ZOLL Proteus Intravascular Temperature 
Management System aimed at demonstrating a clinically rele-
vant reduction in IS by inducing therapeutic hypothermia prior 
to reperfusion by primary PCI.
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